melior discovery

About Us
Our Pipeline
Our Platform
Partnering with Us
News
Contact Us

Click here for the MLR-1023 non-confidential brochure          

melior melior discovery

Melior Pharmaceuticals management team

  Andrew G. Reaume, PhD, MBA
  President and CEO, Co-Founder

  Dr. Reaume has been responsible for building a robust,
  proprietary, clinical candidate pipeline for Melior while
  simultaneously attracting the partnership of many of the
  leading global pharmaceutical companies through Melior’s
  capabilities with in vivo profiling.

Dr. Reaume was previously a Senior Business Analyst at Pfizer, Inc. in the department of genomics and proteomic sciences.  While at Pfizer, he conceived of the idea to create a platform for comprehensively characterizing (phenotyping) genetically modified mice.  He subsequently spearheaded the initiative to build it with a third party collaborator by working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company.

 

From 1993 to 1999 Dr. Reaume worked in R&D at Cephalon where he was principally involved in creating animal models of neurodegenerative disease.  In addition to Dr. Reaume’s research activities, at Cephalon he identified and helped coordinate in-licensing opportunities. 

 

In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management.  He received his PhD in genetics from the University of Connecticut in 1990. 



melior

 

Ramana Kuchibhatla, Ph.D.
Senior VP of Clinical Development & Biostatistics

Dr. Ramana Kuchibhatla received a B.Sc. {Hons} in Mathematics and a M.Sc. in Applied Statistics from the Osmania University in Hyderabad, India.  He worked at ICMR’s Institute for Research in Medical Statistics in Madras in public health and health statistics before joining the Administrative Staff College of India in Hyderabad as a Faculty Member in the Center for Energy, Environment & Technology. 

He joined the University of Iowa Graduate Program in Geography to major in Quantitative Methods and Environmental Studies.  He received his M.A. and Ph.D. from the University of Iowa, Iowa City, IA, USA.  Subsequently, he worked at ManTech Environmental Technology, Inc. a private consulting company specializing in environmental and health assessments where he studied cancer risks of agricultural chemicals. 

 

His pharmaceutical career spans nearly 20 years starting with Glaxo Wellcome (now GlaxoSmithKline) where he consulted in Biostatistics and later in Clinical Research and Development in the Neurology & Psychiatry therapeutic area.  During his tenure, he was involved in the successful filing of two sNDAs that brought Zyban® and Lamictal® (pediatric indication) to market.  In 2001, he joined Targacept, Inc. as Sr. Director of Clinical Research and Development to help setup Clinical Development, Biostatistics and Data Management functions at Targacept Inc.  Dr. Kuchibhatla helped file several INDs for various neuropsychiatric indications as well as bring several NCEs into clinical development with trials conducted in North America, UK, Eastern Europe, and India.  He was closely involved in several successful in-licensing and out-licensing deals Targacept and played a critical role in their successful IPO in June 2006.

 

In April 2007, Dr. Kuchibhatla left Targacept and founded QED Pharmaceutical Services with offices in North Carolina, USA and in Hyderabad, India to offer integrated clinical research consulting services to the pharmaceutical companies. He helped several companies plan and implement clinical development and regulatory activities in USA, Europe (both Eastern and western), and India over the past 9 years.

 

 


melior

 


melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE   John R. Ciallella, Ph.D.
   Director of Research Operations

  

   Dr. Ciallella is Director of Research Operations and is responsible
   for managing  multiple research projects as well as the overall
   operation of the facility.  With 13 years experience in the
   Pharmaceutical industry, Dr. Ciallella has acquired significant
   expertise in preclinical drug discovery and development,

   mainly in CNS and inflammation.  Dr. Ciallella believes that
   optimized in vivo models should be an important screening
component for drug development, specifically for drug repositioning.  

 

As a certified Lean Champion, Dr. Ciallella has worked to develop methods and procedures to optimize efficiencies in research environments and to develop highly integrated and productive research teams.  

Previously Dr. Ciallella was a Senior Research Scientist at Centocor, Inc., a Johnson & Johnson company. Here he was responsible for discovering and assessing neuroprotective biopharmaceuticals, was a member of the CNS Delivery Team, and an integral part of the Molecular Imaging Initiative.  Prior to joining Centocor, Dr. Ciallella was a Research Scientist at Cephalon, Inc., where he led the in vivo screening efforts to identify novel kinase inhibitors for the treatment of Alzheimer’s disease. 

Dr. Ciallella received his Ph.D. from the University of Kentucky Sanders Brown Center on Aging and Department of Microbiology and Immunology.  His postdoctoral training was at the University of Pittsburgh in the lab of Dr. Steven DeKosky, where he studied the biochemical links between traumatic brain injury and Alzheimer’s disease.  Dr. Ciallella has published over 20 peer-reviewed articles, has received grant funding from numerous private and public sources, is a reviewer for several journals, and is a founding member of the International Brain Barriers Society.  Dr. Ciallella enjoys mentoring students and young scientists, and when not working attempts to improve his neglected golf game. 

Dr. Ciallella is the key contact for discussing drug development projects in inflammation and neurological disorders (Alzheimer’s, Parkinson’s, MS).

 

 

Back to top of page

 
home